logo-loader
viewGenprex, Inc.

Genprex reports positive preclinical data on its drug to treat lung cancer

Genprex Inc (NASDAQ: GNPX) CEO Rodney Varner tells Proactive Investors that its collaborators from the University of Texas MD Anderson Cancer Center presented positive preclinical data linked to the company’s Oncoprex immunogene therapy for the treatment of lung cancer at the American Association of Cancer Research meeting.

Varner also spoke about the biotech's most recent strategic hires to its team.

Quick facts: Genprex, Inc.

Price: 0.485 USD

NASDAQ:GNPX
Market: NASDAQ
Market Cap: $7.68 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Genprex's active drug ingredient validated by independent...

Genprex (NASDAQ:GNPX) CEO Rodney Varner tells Proactive that the active ingredient in the biotech firm's immunogene therapy Oncoprex has been shown to prevent tumor growth in triple-negative breast cancer patients by an independent researcher. Varner notes the study was published in the...

4 weeks ago

2 min read